No records
|
663 |
Mangunatmadja I., Indra R.M., Widodo D.P., Rafli A. |
57195717216;57222298152;57215087823;57210824944; |
Risk Factors for Drug Resistance in Epileptic Children with Age of Onset above Five Years: A Case-Control Study |
2021 |
Behavioural Neurology |
2021 |
|
9092824 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119934233&doi=10.1155%2f2021%2f9092824&partnerID=40&md5=74ddaa54df43f8e9dd4e310b0bf1246c |
Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Child Health, Mohammad Hoesin General Hospital, Universitas Sriwijaya, Medical School, Palembang, Indonesia |
Mangunatmadja, I., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Indra, R.M., Department of Child Health, Mohammad Hoesin General Hospital, Universitas Sriwijaya, Medical School, Palembang, Indonesia; Widodo, D.P., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rafli, A., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background. Children with epilepsy with onset above five years encompass distinct epidemiological and clinical characteristics that may have specific risk factors for resistance to antiseizure medications (ASMs). Studies on this age group are limited. Purpose. To identify risk factors for drug resistance in children with epilepsy with the age of onset above five years. Methods. A case-control study was conducted on children with epilepsy with the age of onset above five years visiting the Pediatric Neurology Clinic of Cipto Mangunkusumo and Mohammad Hoesin Hospital between September 2015 and August 2016. Cases consisted of drug-resistant children while control consisted of drug-responsive children according to 2010 ILAE classification. Risk factors studied include onset, number of seizures, illness duration before treatment, cause, seizure type, status epilepticus, initial and evolution of EEG, brain imaging, and initial treatment response. Results. Thirty-two pairs of children were included in the study. After logistic regression analysis, symptomatic etiology and failure to achieve early response to treatment were found to be associated with drug resistance with adjusted OR of 84.71 (95% CI: 5.18-1359.15) and 72.55 (95% CI: 7.08-743.85), respectively. Conclusion. Poor initial response to ASM and symptomatic etiology are independent risk factors for drug resistance in children with epilepsy with the age of onset above five years. © 2021 Irawan Mangunatmadja et al. |
|
anticonvulsive agent; case control study; child; drug resistance; epilepsy; human; onset age; preschool child; risk factor; Age of Onset; Anticonvulsants; Case-Control Studies; Child; Child, Preschool; Drug Resistance; Epilepsy; Humans; Risk Factors |
Hindawi Limited |
09534180 |
|
34804259 |
Article |
Q2 |
859 |
5468 |
|
|
664 |
Han W.M., Law M.G., Choi J.Y., Ditangco R., Kumarasamy N., Chaiwarith R., Ly P.S., Khusuwan S., Merati T.P., Do C.D., Yunihastuti E., Azwa I., Lee M.-P., Pham T.N., Chan Y.-J., Kiertiburanakul S., Ng O.T., Tanuma J., Pujari S., Zhang F., Gani Y., Mave V., Ross J., Avihingsanon A., Ly P.S., Khol V., Zhang F.J., Zhao H.X., Han N., Lee M.P., Li P.C.K., Kwong T.S., Li T.H., Kumarasamy N., Ezhilarasi C., Pujari S., Joshi K., Gaikwad S., Chitalikar A., Sangle S., Mave V., Marbaniang I., Nimkar S., Merati T.P., Wirawan D.N., Yuliana F., Yunihastuti E., Widhani A., Maria S., Karjadi T.H., Tanuma J., Oka S., Nishijima T., Choi J.Y., Na S., Kim J.M., Gani Y.M., Rudi N.B., Azwa I., Kamarulzaman A., SyedOmar S.F., Ponnampalavanar S., Ditangco R., Pasayan M.K., Mationg M.L., Chan Y.J., Ku W.W., Wu P.C., Ke E., Ng O.T., Lim P.L., Lee L.S., Yap T., Ng O.T., Avihingsanon A., Gatechompol S., Phanuphak P., Phadungphon C., Kiertiburanakul S., Phuphuakrat A., Chumla L., Sanmeema N., Chaiwarith R., Sirisanthana T., Praparattanapan J., Nuket K., Khusuwan S., Payoong P., Kantipong P., Kambua P., Pham T.N., Nguyen K.V., Nguyen D.T.H., Nguyen D.T., Do C.D., Ngo A.V., Nguyen L.T., Sohn A.H., Ross J.L., Petersen B., Law M.G., Jiamsakul A., Rupasinghe D., the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific |
57201984684;55556254800;57316129500;55406840800;7003549856;13806165200;9743902800;56166613100;57203678680;56658396600;57221273925;55553159100;57309539000;57213330022;33667461800;6506539792;57350864400;57211702929;57205894660;23007277900;57188842533;24778446900;57193109926;57196347321;57204852770;57188842644;55503803800;35796801900;57206253688;56143671100;57203375227;57350625400;57351089100;55412491000;55413091200;57213607670;35227451500;55273903300;57188839029;6602877716;57425871800;57189801547;56820043000;8935806500;6601921496;57202976978;8850357600;57202561455;57213345044;57219422563;57208428839;57202558648;57226409961;48761023600;57351205400;7601387767;57188842533;57257789600;55553159100;6603019663;55866927600;36768852500;57258598000;57207954173;36936083900;57258255400;55856943500;56514424400;57257813200;57215769524;57210531225;55992506400;57351089200;57203665233;57200282477;57193906863;7004982661;56015716600;57203677438;8277552900;56515326900;55992497800;57203665049;7004277229;35185428900;57192871045;56166613100;57350625500;6603580797;55285745100;57224761710;56370854300;57190300831;56970337500;55035577700;57208054163;41961438300;7006405275;57193720576;56406054800;57222965808;55285745500;57205313395; |
Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV |
2021 |
HIV Medicine |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119685299&doi=10.1111%2fhiv.13211&partnerID=40&md5=043ac7a37890286dc2e8fb917b3e95bc |
The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHSChennai, India; Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia; Bach Mai Hospital, Hanoi, Viet Nam; Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; University Malaya Medical Centre, Kuala Lumpur, Malaysia; Queen Elizabeth Hospital, Hong Kong; National Hospital for Tropical Diseases, Hanoi, Viet Nam; Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore; National Center for Global Health and Medicine, Tokyo, Japan; Institute of Infectious Diseases, Pune, India; Beijing Ditan Hospital, Capital Medical University, Beijing, China; Hospital Sungai Buloh, Sungai Buloh, Malaysia; BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India; TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand |
Han, W.M., The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Law, M.G., The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; Choi, J.Y., Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Ditangco, R., Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHSChennai, India; Chaiwarith, R., Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; Ly, P.S., National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Khusuwan, S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, ; Merati, T.P., Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia; Do, C.D., Bach Mai Hospital, Hanoi, Viet Nam; Yunihastuti, E., Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Azwa, I., University Malaya Medical Centre, Kuala Lumpur, Malaysia, ; Lee, M.-P., Queen Elizabeth Hospital, Hong Kong; Pham, T.N., National Hospital for Tropical Diseases, Hanoi, Viet Nam; Chan, Y.-J., Taipei Veterans General Hospital, Taipei, Taiwan; Kiertiburanakul, S., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Ng, O.T., Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore; Tanuma, J., National Center for Global Health and Medicine, Tokyo, Japan; Pujari, S., Institute of Infectious Diseases, Pune, India; Zhang, F., Beijing Ditan Hospital, Capital Medical University, Beijing, China; Gani, Y., Hospital Sungai Buloh, Sungai Buloh, Malaysia, ; Mave, V., BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India; Ross, J., TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Avihingsanon, A., HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Ly, P.S.; Khol, V.; Zhang, F.J.; Zhao, H.X.; Han, N.; Lee, M.P.; Li, P.C.K.; Kwong, T.S.; Li, T.H.; Kumarasamy, N.; Ezhilarasi, C.; Pujari, S.; Joshi, K.; Gaikwad, S.; Chitalikar, A.; Sangle, S.; Mave, V.; Marbaniang, I.; Nimkar, S.; Merati, T.P.; Wirawan, D.N.; Yuliana, F.; Yunihastuti, E.; Widhani, A.; Maria, S.; Karjadi, T.H.; Tanuma, J.; Oka, S.; Nishijima, T.; Choi, J.Y.; Na, S.; Kim, J.M.; Gani, Y.M., Hospital Sungai Buloh, Sungai Buloh, Malaysia, ; Rudi, N.B.; Azwa, I., University Malaya Medical Centre, Kuala Lumpur, Malaysia, ; Kamarulzaman, A.; SyedOmar, S.F.; Ponnampalavanar, S.; Ditangco, R.; Pasayan, M.K.; Mationg, M.L.; Chan, Y.J.; Ku, W.W.; Wu, P.C.; Ke, E.; Ng, O.T.; Lim, P.L.; Lee, L.S.; Yap, T.; Ng, O.T.; Avihingsanon, A.; Gatechompol, S.; Phanuphak, P.; Phadungphon, C.; Kiertiburanakul, S.; Phuphuakrat, A.; Chumla, L.; Sanmeema, N.; Chaiwarith, R.; Sirisanthana, T.; Praparattanapan, J.; Nuket, K.; Khusuwan, S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, ; Payoong, P.; Kantipong, P.; Kambua, P.; Pham, T.N.; Nguyen, K.V.; Nguyen, D.T.H.; Nguyen, D.T.; Do, C.D.; Ngo, A.V.; Nguyen, L.T.; Sohn, A.H.; Ross, J.L.; Petersen, B.; Law, M.G.; Jiamsakul, A.; Rupasinghe, D.; the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific |
Objectives: We investigated weight changes following antiretroviral therapy (ART) initiation, the development of metabolic syndrome (MetS) and its association with all-cause mortality among Asian adults living with HIV. Methods: Participants enrolled in a regional Asian HIV-infected cohort with weight and height measurements at ART initiation were eligible for inclusion in the analysis. Factors associated with weight changes and incident MetS (according to the International Diabetic Federation (IDF) definition) were analysed using linear mixed models and Cox regression, respectively. Competing-risk regression models were used to investigate the association of MetS with all-cause mortality. Results: Among 4931 people living with HIV (PLWH), 66% were male. At ART initiation, the median age was 34 [interquartile range (IQR) 29–41] years, and the median (IQR) weight and body mass index (BMI) were 55 (48–63) kg and 20.5 (18.4–22.9) kg/m2, respectively. At 1, 2 and 3 years of ART, overall mean (± standard deviation) weight gain was 2.2 (±5.3), 3.0 (±6.2) and 3.7 (±6.5) kg, respectively. Participants with baseline CD4 count ≤ 200 cells/µL [weight difference (diff) = 2.2 kg; 95% confidence interval (CI) 1.9–2.5 kg] and baseline HIV RNA ≥ 100 000 HIV-1 RNA copies/mL (diff = 0.6 kg; 95% CI 0.2–1.0 kg), and those starting with integrase strand transfer inhibitor (INSTI)-based ART (diff = 2.1 kg; 95% CI 0.7–3.5 kg vs. nonnucleoside reverse transcriptase inhibitors) had greater weight gain. After exclusion of those with abnormal baseline levels of MetS components, 295/3503 had incident MetS [1.18 (95% CI 1.05–1.32)/100 person-years (PY)]. The mortality rate was 0.7 (95% CI 0.6–0.8)/100 PY. MetS was not significantly associated with all-cause mortality in the adjusted model (P = 0.236). Conclusions: Weight gain after ART initiation was significantly higher among those initiating ART with lower CD4 count, higher HIV RNA and an INSTI-based regimen after controlling for baseline BMI. Greater efforts to identify and manage MetS among PLWH are needed. © 2021 British HIV Association |
all-cause mortality; Asian people living with HIV; HIV/AIDS; metabolic syndrome; weight gain |
|
John Wiley and Sons Inc |
14642662 |
|
34816562 |
Article |
Q1 |
1530 |
2201 |
|
|
666 |
Sukrisman L., Sinto R. |
8661764000;36099377100; |
Coagulation profile and correlation between D-dimer, inflammatory markers, and COVID-19 severity in an Indonesian national referral hospital |
2021 |
Journal of International Medical Research |
49 |
11 |
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119613636&doi=10.1177%2f03000605211059939&partnerID=40&md5=c946e5b0ffec2b5ef4b8bd521da19dbf |
Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia |
Sukrisman, L., Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Sinto, R., Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia |
Background: Coagulopathy and inflammation are associated with coronavirus disease 2019 (COVID-19) severity. This study assessed D-dimer concentration and its correlation with inflammatory markers and COVID-19 severity. Methods: This was a retrospective cross-sectional study involving 194 COVID-19 cases, with the severity of infection graded in accordance with the World Health Organization (WHO) guidelines. We measured D-dimer, C-reactive protein (CRP), and ferritin on admission and determined the cutoff values for D-dimer and CRP and evaluated the correlation between D-dimer and CRP and ferritin. Results: Median D-dimer, CRP, and ferritin concentrations were 2240 µg/L, 73.2 mg/L, and 1173.8 µg/mL, respectively. The highest median D-dimer value was seen in mild and moderate acute respiratory distress syndrome (ARDS). The highest ferritin concentration was seen in severe ARDS. There was a significant correlation between D-dimer value and CRP (r = 0.327), but no significant correlation between D-dimer and ferritin (r = 0.101). The area under the receiver operating characteristic curve (AUC) for the combination of CRP ≥72.65 mg/L and D-dimer ≥1250 µg/L as a marker of COVID-19 severity was 0.722 (95% confidence interval (CI): 0.615–0.781). Conclusion: The combination of CRP ≥72.65 mg/L and D-dimer ≥1250 µg/L can be used as marker of COVID-19 severity, with moderate accuracy. © The Author(s) 2021. |
acute respiratory distress syndrome; C-reactive protein; Coronavirus disease 2019; correlation; D-dimer; ferritin; inflammation; severity |
biological marker; fibrin degradation product; fibrin fragment D; cross-sectional study; hospital; human; Indonesia; patient referral; retrospective study; severity of illness index; Biomarkers; COVID-19; Cross-Sectional Studies; Fibrin Fibrinogen Degradation Products; Hospitals; Humans; Indonesia; Referral and Consultation; Retrospective Studies; SARS-CoV-2; Severity of Illness Index |
SAGE Publications Ltd |
03000605 |
|
34796762 |
Article |
Q3 |
421 |
11626 |
|
|
667 |
Lesmana C.R.A., Paramitha M.S., Gani R.A., Lesmana L.A. |
8977683000;57212562901;23495930300;55920139300; |
The role of endoscopic ultrasound for portal hypertension in liver cirrhosis |
2021 |
Journal of Medical Ultrasonics |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119500644&doi=10.1007%2fs10396-021-01165-4&partnerID=40&md5=72338502ade4f82a944b72db4fee4c65 |
Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia |
Lesmana, C.R.A., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia, Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia; Paramitha, M.S., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Gani, R.A., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Lesmana, L.A., Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia |
Chronic liver disease is still a major problem because disease progression will ultimately lead to liver cirrhosis. Portal hypertension is the hallmark in advanced liver disease management. By establishing portal vein access, endoscopic ultrasound (EUS) has been utilized in various clinical applications. In comparison to standard upper gastrointestinal endoscopy, EUS-Doppler has been shown to be a better modality for detecting esophageal and gastric varices along with peri-esophageal collateral veins, para-esophageal collateral veins, and perforating veins, and may be used to objectively predict the recurrence of bleeding. EUS-guided portal vein catheterization has also been proposed to overcome the limitations of trans-jugular approaches. The combination of EUS-elastography and azygos vein evaluation can also enhance the diagnostic accuracy of each modality. Another well-known implementation of EUS-guided procedures is in the management of ascites; particularly in paracentesis and ascitic fluid analysis. In addition, the most common clinical application of EUS in the treatment of portal hypertension is through vascular therapy or creation of intrahepatic portosystemic shunts. Major drawbacks of EUS mainly revolve around technical difficulties, the high cost of the procedure, as well as the requirement of more studies in humans to evaluate EUS-guided advanced therapeutic modalities in portal hypertension. © 2021, The Author(s), under exclusive licence to The Japan Society of Ultrasonics in Medicine. |
Endoscopic ultrasound; Liver cirrhosis; Portal hypertension |
|
Springer |
13464523 |
|
|
Review |
#N/A |
#N/A |
#N/A |
|
|
669 |
Syafira N., Graudins A., Yarema M., Wong A. |
57222178056;55790181600;8550407600;52265101200; |
Comparing development of liver injury using the two versus three bag acetylcysteine regimen despite early treatment in paracetamol overdose |
2021 |
Clinical Toxicology |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119253032&doi=10.1080%2f15563650.2021.1998518&partnerID=40&md5=71ecde369075113c2b3f41b9bb20e452 |
Department of Medicine, School of Clinical Science at Monash Health, Monash UniversityVIC, Australia; Faculty of Medicine, Universitas Indonesia, Special Capital Region of Jakarta, Indonesia; Monash Toxicology Unit, Dandenong Hospital, Monash HealthVIC, Australia; Poison and Drug Information Service, Alberta Health Services, Calgary, Canada; Department of Emergency Medicine, University of Calgary, Calgary, Canada; Austin Toxicology Unit, Austin HealthVIC, Australia; Department of Critical Care, University of MelbourneVIC, Australia |
Syafira, N., Department of Medicine, School of Clinical Science at Monash Health, Monash UniversityVIC, Australia, Faculty of Medicine, Universitas Indonesia, Special Capital Region of Jakarta, Indonesia; Graudins, A., Department of Medicine, School of Clinical Science at Monash Health, Monash UniversityVIC, Australia, Monash Toxicology Unit, Dandenong Hospital, Monash HealthVIC, Australia; Yarema, M., Poison and Drug Information Service, Alberta Health Services, Calgary, Canada, Department of Emergency Medicine, University of Calgary, Calgary, Canada; Wong, A., Department of Medicine, School of Clinical Science at Monash Health, Monash UniversityVIC, Australia, Austin Toxicology Unit, Austin HealthVIC, Australia, Department of Critical Care, University of MelbourneVIC, Australia |
Introduction: Some studies have reported that early administration of acetylcysteine using a 3-bag regimen may not fully prevent development of liver injury in some patients. We compared the incidence of acute liver injury (ALI) in patients receiving acetylcysteine within eight hours of ingestion between the two-bag acetylcysteine regimen (200 mg/kg over four hours, 100 mg/kg over 16 h) and the three-bag regimen (150 mg/kg over 1 h, 50 mg/kg over 4 h, 100 mg/kg over 16 h). Method: This was a retrospective cohort study of the two-bag and three-bag acetylcysteine regimens from Monash Health, Victoria, Australia (2009–2020), compared to the three-bag acetylcysteine regimen data from the Canadian Acetaminophen Overdose Study (CAOS) database (1980–2005). The inclusion criteria included patients with an acute single ingestion of paracetamol; normal aminotransferases on presentation and acetylcysteine administered within eight hours post-overdose. The primary outcome was development of ALI (defined as: peak aminotransferase >150 IU/L). Results: At Monash Health, 191 patients were treated with the two-bag acetylcysteine regimen, and 180 patients with the three-bag regimen. The CAOS cohort provided 515 patients treated with the three-bag regimen. ALI developed in 1.6% (3/191) of the two-bag Monash Health group, 2.2% (4/180) of the three-bag Monash Health group (difference −0.6%, p 0.7), and 2.9% (15/515) of the three-bag CAOS group (difference compared to two-bag −1.3%, p 0.4). Hepatotoxicity (ALT >1000) developed in 0.5% (1/191) of patients treated with the two-bag regimen, 1.7% (3/180) in the Monash Health three-bag regimen and 1% (5/515) of the three-bag CAOS group. There were no statistically significant differences between groups. Conclusions: ALI and hepatotoxicity were observed in a small, comparable percentage of patients despite early acetylcysteine administration using the two-bag and three-bag regimens. Repeating blood tests at the end of acetylcysteine treatment will identify these patients and indicate those requiring continuation of acetylcysteine. © 2021 Informa UK Limited, trading as Taylor & Francis Group. |
Acetaminophen; acute liver injury; hepatotoxicity |
|
Taylor and Francis Ltd. |
15563650 |
|
|
Article |
Q2 |
840 |
5641 |
|
|
671 |
Irawan C., Rachman A., Rahman P., Mansjoer A. |
28767651600;15056701600;57336745700;24335647800; |
Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients |
2021 |
Journal of Cancer Epidemiology |
2021 |
|
1103631 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118993816&doi=10.1155%2f2021%2f1103631&partnerID=40&md5=82e487803fe00d9c97bbac4301d585e1 |
Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Clinical Epidemiology Unit, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Irawan, C., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rachman, A., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rahman, P., Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Mansjoer, A., Clinical Epidemiology Unit, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background. The three-year survival rate of locally advanced nasopharyngeal carcinoma (NPC) patients in Indonesia is lower than in other Asian countries. Calculation of hemoglobin-to-platelet ratio (HPR) may become a more practical predictor than the ratios using leukocyte cell components. Yet, no study has been conducted to investigate the potential of HPR in predicting survival outcomes in locally advanced nasopharyngeal cancer patients. Objective. To determine the role of pretreatment hemoglobin-to-platelet ratio in predicting the three-year overall survival (OS) of locally advanced NPC. Method. A retrospective cohort study followed up on 289 locally advanced NPC patients who had undergone therapy at the Dr. Cipto Mangunkusumo National General Hospital between January 2012 and October 2016. HPR cut-off was determined using ROC. Subjects were classified into two groups according to the HPR value. Kaplan-Meier curve was utilized to illustrate patients' three-year survival, and Cox regression test analyzed confounding variables to yield an adjusted hazard ratio (HR). Results. The optimal cut-off for HPR was 0.362 (AUC 0.6228, 95% CI: 0.56-0.69, sensitivity 61.27%, specificity 60.34%). Of the subjects, 48.44% had HPR≤0.362, and they had a higher three-year mortality rate than those with HPR>0.362 (50% vs. 31.54%). In bivariate analysis, HPR≤0.362 and age≥60 significantly showed a worse three-year OS (p value = 0.003 and 0.075, respectively). In multivariate analysis, we concluded that a pretreatment HPR≤0.362 was an independent negative predictor of three-year OS in locally advanced NPC patients (adjusted HR 1.82; 95% CI: 1.25-2.65). Conclusion. Pretreatment HPR≤0.362 was a negative predictor of three-year OS in locally advanced nasopharyngeal cancer patients. © 2021 Cosphiadi Irawan et al. |
|
antineoplastic agent; hemoglobin; adjuvant therapy; adult; advanced cancer; area under the curve; Article; cancer chemotherapy; cancer mortality; cancer patient; cancer prognosis; cancer radiotherapy; cancer survival; clinical outcome; cohort analysis; conformal radiotherapy; controlled study; female; follow up; general hospital; hematological parameters; hemoglobin blood level; hemoglobin to platelet ratio; human; human cell; intensity modulated radiation therapy; locally advanced nasopharyngeal carcinoma; major clinical study; male; middle aged; multiple cycle treatment; nasopharynx carcinoma; neoadjuvant chemotherapy; nutritional status; overall survival; platelet count; receiver operating characteristic; reference value; retrospective study; sensitivity and specificity; survival predic |
Hindawi Limited |
16878558 |
|
|
Article |
Q2 |
783 |
6201 |
|
|
672 |
Tunjungputri R.N., Tetrasiwi E.N., Veronica M., Pandelaki J., Ibrahim F., Nelwan E.J. |
56342194400;57267704700;57268337000;35759266900;54886001500;14527452900; |
Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
2021 |
Case Reports in Medicine |
2021 |
|
9673453 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118971098&doi=10.1155%2f2021%2f9673453&partnerID=40&md5=ddb9dd4ce5b8de10f0e4c9c43c6cd496 |
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Radiology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Microbiology Department, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Infectious Disease and Immunology Research Center - IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Tunjungputri, R.N., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Tetrasiwi, E.N., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Veronica, M., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Pandelaki, J., Department of Radiology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Ibrahim, F., Microbiology Department, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nelwan, E.J., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia, Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia, Infectious Disease and Immunology Research Center - IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Introduction. The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake. Conclusion. We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination. © 2021 Rahajeng N. Tunjungputri et al. |
|
C reactive protein; coronavac; D dimer; fibrinogen; hemoglobin; neutralizing antibody; procalcitonin; adult; antibody titer; Article; asymptomatic coronavirus disease 2019; blood pressure; calcitonin blood level; case report; clinical article; coronavirus disease 2019; COVID-19 testing; electrocardiography; fibrinogen blood level; heart right bundle branch block; hemoglobin blood level; hospital admission; human; hyperglycemia; hypokalemia; hyponatremia; hypoosmolarity; inflammation; laboratory test; leukocyte count; lung examination; male; medical history; middle aged; physical examination; platelet count; protein blood level; real time polymerase chain reaction; thorax radiography; vaccination; vaccine associated disease enhancement; vaccine associated disease enhancement; young adult |
Hindawi Limited |
16879627 |
|
|
Article |
Q4 |
200 |
19317 |
|
|
676 |
Agarwal A., Sharma R.K., Gupta S., Boitrelle F., Finelli R., Parekh N., Durairajanayagam D., Saleh R., Arafa M., Cho C.L., Farkouh A., Rambhatla A., Henkel R., Vogiatzi P., Tadros N., Kavoussi P., Ko E., Leisegang K., Kandil H., Palani A., Salvio G., Mostafa T., Rajmil O., Banihani S.A., Schon S., Le T.V., Birowo P., Çeker G., Alvarez J., Molina J.M.C., Ho C.C.K., Calogero A.E., Khalafalla K., Duran M.B., Kuroda S., Colpi G.M., Zini A., Anagnostopoulou C., Pescatori E., Chung E., Caroppo E., Dimitriadis F., Pinggera G.-M., Busetto G.M., Balercia G., Elbardisi H., Taniguchi H., Park H.J., Rosas I.M., de la Rosette J., Ramsay J., Bowa K., Simopoulou M., Rodriguez M.G., Sabbaghian M., Martinez M., Gilani M.A.S., Al-Marhoon M.S., Kosgi R., Cannarella R., Micic S., Fukuhara S., Parekattil S., Jindal S., Abdel-Meguid T.A.-A., Morimoto Y., Shah R. |
7401480880;56464514400;8924915200;35306701900;57210196522;57196694810;55520166400;7006807491;23098964500;57197761284;57208753862;23398404000;16194084100;55926424800;6701691160;13805293700;54894624400;55522599700;57225096159;57195328571;57191592841;14060837800;6602414666;55393128900;36119073400;57327390400;6504153311;57445145100;7402573357;57214102315;57327957600;7006656219;57188552644;57216609982;57327256700;7004721256;7005212511;57225111834;7003338300;57327111700;6602342322;15126468500;6603547664;37049750600;56259951900;56711976600;22836833700;57327528100;57225111015;7102844406;7103327153;24721453900;6506988003;57225094450;24451370900;57214939051;57327818500;9247352000;57195955297;56033761100;7006493137;8635237400;6506341654;57214937086;6508134167;36051984500;23470471000; |
Sperm vitality and necrozoospermia: diagnosis, management, and results of a global survey of clinical practice |
2021 |
World Journal of Men's Health |
39 |
|
210149 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118736952&doi=10.5534%2fwjmh.210149&partnerID=40&md5=776ce144f9bcad4451df84b64415ccd7 |
American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Reproductive Biology, Fertility Preservation, Andrology, CECOS, Poissy Hospital, Poissy, France; Paris Saclay University, UVSQ, INRAE, BREED, Jouy-en-Josas, France; Department of Urology, Cleveland Clinic, Cleveland, OH, United States; Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor, Malaysia; Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt; Department of Urology, Hamad Medical Corporation, Doha, Qatar; Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar; SH Ho Urology Center, Department of Surgery, Chinese University of Hong Kong, Hong Kong; Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, United States; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom; Department of Medical Bioscience, University of the Western Cape, Bellville, South Africa; LogixX Pharma, Berkshire, Theale, United Kingdom; Andromed Health and Reproduction, Fertility Diagnostics Laboratory, Maroussi, Greece; Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, United States; Austin Fertility and Reproductive Medicine/Westlake IVF, Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States; Department of Urology, Loma Linda University Health, Loma Linda, CA, United States; Department of Physiology, School of Natural Medicine, Faculty of Community and Health Sciences, University of the Western Cape, Bellville, South Africa; Fakih IVF Fertility Center, Abu Dhabi, United Arab Emirates; Department of Biochemistry, College of Medicine, University of Garmian, Kalar, Iraq; Department of Endocrinology and Metabolic Diseases, Polytechnic University of Marche, Ancona, Italy; Department of Andrology, Sexology and STIs, Faculty of Medicina, Cairo University, Cairo, Egypt; Department of Andrology, Fundacio Puigvert, Barcelona, Spain; Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, United States; Department of Andrology and Urology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam; Department of Andrology, Binh Dan Hospital, Ho Chi Minh City, Viet Nam; Department of Urology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Urology, Samsun Vezirköprü State Hospital, Samsun, Turkey; Centro ANDROGEN, La Coruña, Spain; Servicio de Urología, Hospital Clínico de Barcelona, Barcelona, Spain; Department of Surgery, School of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Department of Urology, Samsun Training and Research Hospital, Samsun, Turkey; Andrology and IVF Unit, Procrea Institute, Lugano, Switzerland; Department of Surgery, McGill University, Montreal, QC, Canada; IVF Clinic “Akeso-Embryo ART”, Athens, Greece; Andrology and Reproductive Medicine Unit, Gynepro Medical, Bologna, Italy; Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia; AndroUrology Centre, Brisbane, QLD, Australia; Reproductive and IVF Unit, Andrology Outpatients Clinic, ASL Bari, Conversano (Ba), Italy; 1st Urology Department, School of Medicine, Aristotle University, Thessaloniki, Greece; Department of Urology, Innsbruck Medical University, Innsbruck, Austria; Department of Urology and Renal Transplantation, University of Foggia, Ospedali Riuniti of Foggia, Foggia, Italy; Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan; Department of Urology, Pusan National University School of Medicine, Busan, South Korea; Medical Research Institute, Pusan National University Hospital, Busan, South Korea; Citmer Reproductive Medicine, IVF LAB, Mexico City, Mexico; Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey; Department of Andrology, Hammersmith Hospital, London, United Kingdom; Department of Urology, Michael Chilufya Sata Copperbelt University School of Medicine, Ndola, Zambia; Department of Experimental Physiology, School of Health Sciences, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Departamento Docencia e Investigación, Hospital Militar Campo de Mayo, Universidad Barcelo, Buenos Aires, Argentina; Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran; Section of Urology, University of Santo Tomas Hospital, Manila, Philippines; Department of Surgery, Urology Division, Sultan Qaboos University, Muscat, Oman; Department of Urology and Andrology, AIG Hospitals, Gachibowli, Hyderabad, India; Department of Andrology, Uromedica Polyclinic, Belgrade, Serbia; Department of Urology, Graduate School of Medicine, Osaka University, Osaka, Japan; Avant Concierge Urology, University of Central Florida, Winter Garden, FL, United States; Department of Andrology and Reproductive Medicine, Jindal Hospital, Meerut, India; Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt; Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; HORAC Grand Front Osaka Clinic, Osaka, Japan; Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India |
Agarwal, A., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Sharma, R.K., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Gupta, S., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Boitrelle, F., Reproductive Biology, Fertility Preservation, Andrology, CECOS, Poissy Hospital, Poissy, France, Paris Saclay University, UVSQ, INRAE, BREED, Jouy-en-Josas, France; Finelli, R., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Parekh, N., Department of Urology, Cleveland Clinic, Cleveland, OH, United States; Durairajanayagam, D., Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor, Malaysia; Saleh, R., Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt; Arafa, M., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States, Department of Urology, Hamad Medical Corporation, Doha, Qatar, Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar; Cho, C.L., SH Ho Urology Center, Department of Surgery, Chinese University of Hong Kong, Hong Kong; Farkouh, A., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Rambhatla, A., Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, United States; Henkel, R., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom, Department of Medical Bioscience, University of the Western Cape, Bellville, South Africa, LogixX Pharma, Berkshire, Theale, United Kingdom; Vogiatzi, P., Andromed Health and Reproduction, Fertility Diagnostics Laboratory, Maroussi, Greece; Tadros, N., Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, United States; Kavoussi, P., Austin Fertility and Reproductive Medicine/Westlake IVF, Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States; Ko, E., Department of Urology, Loma Linda University Health, Loma Linda, CA, United States; Leisegang, K., Department of Physiology, School of Natural Medicine, Faculty of Community and Health Sciences, University of the Western Cape, Bellville, South Africa; Kandil, H., Fakih IVF Fertility Center, Abu Dhabi, United Arab Emirates; Palani, A., Department of Biochemistry, College of Medicine, University of Garmian, Kalar, Iraq; Salvio, G., Department of Endocrinology and Metabolic Diseases, Polytechnic University of Marche, Ancona, Italy; Mostafa, T., Department of Andrology, Sexology and STIs, Faculty of Medicina, Cairo University, Cairo, Egypt; Rajmil, O., Department of Andrology, Fundacio Puigvert, Barcelona, Spain; Banihani, S.A., Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan; Schon, S., Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, United States; Le, T.V., Department of Andrology and Urology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam, Department of Andrology, Binh Dan Hospital, Ho Chi Minh City, Viet Nam; Birowo, P., Department of Urology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Çeker, G., Department of Urology, Samsun Vezirköprü State Hospital, Samsun, Turkey; Alvarez, J., Centro ANDROGEN, La Coruña, Spain; Molina, J.M.C., Servicio de Urología, Hospital Clínico de Barcelona, Barcelona, Spain; Ho, C.C.K., Department of Surgery, School of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia; Calogero, A.E., Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Khalafalla, K., Department of Urology, Hamad Medical Corporation, Doha, Qatar; Duran, M.B., Department of Urology, Samsun Training and Research Hospital, Samsun, Turkey; Kuroda, S., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Colpi, G.M., Andrology and IVF Unit, Procrea Institute, Lugano, Switzerland; Zini, A., Department of Surgery, McGill University, Montreal, QC, Canada; Anagnostopoulou, C., IVF Clinic “Akeso-Embryo ART”, Athens, Greece; Pescatori, E., Andrology and Reproductive Medicine Unit, Gynepro Medical, Bologna, Italy; Chung, E., Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia, AndroUrology Centre, Brisbane, QLD, Australia; Caroppo, E., Reproductive and IVF Unit, Andrology Outpatients Clinic, ASL Bari, Conversano (Ba), Italy; Dimitriadis, F., 1st Urology Department, School of Medicine, Aristotle University, Thessaloniki, Greece; Pinggera, G.-M., Department of Urology, Innsbruck Medical University, Innsbruck, Austria; Busetto, G.M., Department of Urology and Renal Transplantation, University of Foggia, Ospedali Riuniti of Foggia, Foggia, Italy; Balercia, G., Department of Endocrinology and Metabolic Diseases, Polytechnic University of Marche, Ancona, Italy; Elbardisi, H., Department of Urology, Hamad Medical Corporation, Doha, Qatar, Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar; Taniguchi, H., Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan; Park, H.J., Department of Urology, Pusan National University School of Medicine, Busan, South Korea, Medical Research Institute, Pusan National University Hospital, Busan, South Korea; Rosas, I.M., Citmer Reproductive Medicine, IVF LAB, Mexico City, Mexico; de la Rosette, J., Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey; Ramsay, J., Department of Andrology, Hammersmith Hospital, London, United Kingdom; Bowa, K., Department of Urology, Michael Chilufya Sata Copperbelt University School of Medicine, Ndola, Zambia; Simopoulou, M., Department of Experimental Physiology, School of Health Sciences, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Rodriguez, M.G., Departamento Docencia e Investigación, Hospital Militar Campo de Mayo, Universidad Barcelo, Buenos Aires, Argentina; Sabbaghian, M., Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran; Martinez, M., Section of Urology, University of Santo Tomas Hospital, Manila, Philippines; Gilani, M.A.S., Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran; Al-Marhoon, M.S., Department of Surgery, Urology Division, Sultan Qaboos University, Muscat, Oman; Kosgi, R., Department of Urology and Andrology, AIG Hospitals, Gachibowli, Hyderabad, India; Cannarella, R., Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Micic, S., Department of Andrology, Uromedica Polyclinic, Belgrade, Serbia; Fukuhara, S., Department of Urology, Graduate School of Medicine, Osaka University, Osaka, Japan; Parekattil, S., Avant Concierge Urology, University of Central Florida, Winter Garden, FL, United States; Jindal, S., Department of Andrology and Reproductive Medicine, Jindal Hospital, Meerut, India; Abdel-Meguid, T.A.-A., Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt, Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Morimoto, Y., HORAC Grand Front Osaka Clinic, Osaka, Japan; Shah, R., Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India |
Sperm vitality testing is a basic semen examination that has been described in the World Health Organization (WHO) Laboratory Manual for the Examination and Processing of Human Semen from its primary edition, 40 years ago. Several methods can be used to test sperm vitality, such as the eosin-nigrosin (E-N) stain or the hypoosmotic swelling (HOS) test. In the 6th (2021) edition of the WHO Laboratory Manual, sperm vitality assessment is mainly recommended if the total motility is less than 40%. Hence, a motile spermatozoon is considered alive, however, in certain conditions an immotile spermatozoon can also be alive. Therefore, the differentiation between asthenozoospermia (pathological decrease in sperm motility) and necrozoospermia (pathological decrease in sperm vitality) is important in directing further investigation and management of infertile patients. The causes leading to necrozoospermia are diverse and can either be local or general, testicular or extra-testicular. The andrological management of necrozoospermia depends on its etiology. However, there is no standardized treatment available presently and practice varies among clinicians. In this study, we report the results of a global survey to understand current practices regarding the physician order of sperm vitality tests as well as the management practices for necrozoospermia. Laboratory and clinical scenarios are presented to guide the reader in the management of necrozoospermia with the overall objective of establishing a benchmark ranging from the diagnosis of necrozoospermia by sperm vitality testing to its clinical management. Copyright © 2021 Korean Society for Sexual Medicine and Andrology |
Asthenozoospermia; Eosine Yellowish-(YS); Infertility; Nigrosin; Spermatozoa; Vitality |
asthenospermia; clinical practice; diagnostic procedure; ejaculation; eosin nigrosin staining; human; hypoosmotic swelling test; infertility therapy; intracytoplasmic sperm injection; male infertility; necrozoospermia; physician; quality control; Review; semen analysis; semen parameters; sperm viability; spermatozoon density; spermatozoon motility; testicular sperm extraction |
Korean Society for Sexual Medicine and Andrology |
22874208 |
|
|
Review |
#N/A |
#N/A |
#N/A |
|
|
678 |
Sulistio S., Habib H., Mulyana R.M., Albar I.A. |
57216916380;57216916669;57216915765;57216915796; |
Emergency intubation practices in a tertiary teaching hospital in Jakarta, Indonesia: A prospective observational study |
2021 |
EMA - Emergency Medicine Australasia |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118592756&doi=10.1111%2f1742-6723.13890&partnerID=40&md5=f148a4a939c1e802197c4a35882c3a66 |
Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Sulistio, S., Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Habib, H., Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Mulyana, R.M., Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Albar, I.A., Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Objective: Intubation is an important competency for emergency doctors. Emergency patients are often unstable, with undifferentiated conditions. There is little time to prepare these patients prior to intubation and so ED intubation may differ from intubation in intensive care units and operating theatres. The present study aims to describe the characteristics of emergency intubation after an administrative policy change within a tertiary teaching hospital in Jakarta, allowing non-anaesthetists to perform intubation in the ED. Methods: Prospective data were collected regarding patients of all age groups who were intubated at the ED of Cipto Mangunkusumo General Hospital, Jakarta, from February 2018 to January 2019. Patient characteristics, intubation attempts, medications used, complications, and disposition were recorded in a self-reported airway registry based on the Australian and New Zealand Emergency Department Airway Registry (ANZEDAR) form. Results: During the 12-month study period, 231 patients, or 41.5% of ED intubated patients were enrolled in the study, and there were 268 intubation attempts on these enrolled patients. The first-pass success rate was 207 out of 231 patients, or 89.6%, with anaesthetist (88.9%), better than emergency doctors (55.4%). Complications were reported in 51 patients, or 22.0%, with desaturation and hypotension being the most common. Thirty-three patients, or 14.3%, died in the ED before being transferred to another unit. Conclusions: The first-pass success rate is comparable with international data. Non-anaesthetic physicians must improve their experience to achieve a favourable success rate. The data on complications highlight the need for improvement in Indonesian ED intubation practices. © 2021 Australasian College for Emergency Medicine |
airway complications; airway management; emergency medicine; rapid sequence intubation; registry |
|
John Wiley and Sons Inc |
17426731 |
|
|
Article |
Q2 |
602 |
8388 |
|
|
680 |
Sandora N., Putra M.A., Nurhayati R.W., Suwarti, Nauli R., Kusuma T.R., Fitria N.A., Ardiansyah, Muttaqin C., Makdinata W., Alwi I. |
57204103434;57215605850;55748436600;57212462722;57212478305;57222897694;57148498800;57223036386;57226442135;57223405655;15055173800; |
Characterisation of the single-cell human cardiomyocytes taken from the excess heart tissue of the right ventricular outlet in congenital heart disease |
2021 |
Cell and Tissue Banking |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118214107&doi=10.1007%2fs10561-021-09970-4&partnerID=40&md5=2c4fad90958206777aa1ef5e9ea1e5ec |
Faculty of Medicine, Universitas Riau, Pekanbaru, 28293, Indonesia; Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia |
Sandora, N., Faculty of Medicine, Universitas Riau, Pekanbaru, 28293, Indonesia, Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Putra, M.A., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Nurhayati, R.W., Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Suwarti, Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Nauli, R., Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Kusuma, T.R., Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Fitria, N.A., Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Ardiansyah, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Muttaqin, C., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Makdinata, W., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Alwi, I., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia |
Cardiovascular disease is the second highest cause of death across the globe. Myocardial infarction is one of the heart diseases that cause permanent impairment of the heart wall leads to heart failure. Cellular therapy might give hope to regenerate the damaged myocardium. Single cells isolated from an excess heart tissue obtained from the correction of the right ventricular hypertrophy in patients with Tetralogy of Fallot for future heart study were investigated. Methods: Once resected, the heart tissues were transported at 37 °C, in Dulbecco's Modified Eagle's medium/ DMEM (4.5 g.L−1, antibiotic–antimycotic 3x, PRP10% (v/v)), to reach the lab within 30 min, weighted and grouped into less than 500 mg and more than 1000 mg (n = 4). Each sample was digested with 250 U.mL−1 Collagenase type V and 4U.mL−1 Proteinase XXIV in the MACS™ C-tube (Milltenyi, Germany), then dissociated using the MACS™ Octo Dissociator with Heater (Milltenyi, Germany) for 60 min at 37 °C. Results: All cells isolated were rod-shaped cells; viability was up to 90%. The cell density obtained from the 500 mg group were 4,867 ± 899 cells.mg−1 tissue weight, significantly higher compared to the 1,000 mg group; had 557 ± 490 cells.mg−1 tissue weight (mean of (n = 3) ± 95% C.l). The isolated cells were analyzed using FACs BD Flowcytometer, expressed cTnT + 13.38%, PECAM-1 + /VCAM-1- 32.25%, cKit + 7.85%, ICAM + 85.53%, indicating the cardiomyocyte progenitor cells. Conclusion: Cardiomyocytes taken from the wasted heart tissue might be a candidate of cardiomyocytes source to study interventions to the heart as it contained up to 13.38% cardiomyocytes, and 32.25% of cardiac progenitor cells. Moreover, perhaps when cardiac cell therapy needs autologous cardiomyocytes, less than 500 mg tissue weight can be considered as sufficient. © 2021, The Author(s), under exclusive licence to Springer Nature B.V. |
Cardiac progenitor cells; Cardiomyocyte isolation; Right ventricular resection; Tetralogy of fallot; Waste heart tissue |
|
Springer Science and Business Media B.V. |
13899333 |
|
|
Article |
Q3 |
397 |
12196 |
|
|